ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Newellis Inc

Newellis Inc (NUWE)

1.00
-0.01
(-0.99%)
Cerrado 21 Diciembre 3:00PM
1.02
0.02
(2.00%)
Fuera de horario: 6:29PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
1.02
Postura de Compra
0.93
Postura de Venta
1.20
Volume Operado de la Acción
190,121
1.00 Rango del Día 1.07
0.9237 Rango de 52 semanas 30.10
Capitalización de Mercado [m]
Precio Anterior
1.01
Precio de Apertura
1.01
Última hora de negociación
Volumen financiero
US$ 196,337
Precio Promedio Ponderado
1.0327
Volumen promedio (3 m)
2,993,585
Acciones en circulación
4,373,968
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.02
Beneficio por acción (BPA)
-5.17
turnover
8.86M
Beneficio neto
-22.63M

Acerca de Newellis Inc

Nuwellis Inc is a medical device company. Its solutions include Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidne... Nuwellis Inc is a medical device company. Its solutions include Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flow, automatically displaying real-time data to the medical staff. Mostrar más

Sector
Electromedical Apparatus
Industria
Electromedical Apparatus
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Newellis Inc is listed in the Electromedical Apparatus sector of the NASDAQ with ticker NUWE. The last closing price for Newellis was US$1.01. Over the last year, Newellis shares have traded in a share price range of US$ 0.9237 to US$ 30.10.

Newellis currently has 4,373,968 shares in issue. The market capitalisation of Newellis is US$4.42 million. Newellis has a price to earnings ratio (PE ratio) of -1.02.

NUWE Últimas noticias

Nuwellis Regains Compliance with Nasdaq Listing Requirements

MINNEAPOLIS, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (the “Company” or “Nuwellis”) today announced that the Company received formal written notice from The Nasdaq Stock...

Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights

MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company focused on transforming the lives of people with fluid overload, today reported financial...

Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company committed to transforming the lives of...

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

Reimbursement rate to increase 397% per day effective January 1, 2025 New rate expected to encourage adoption of ultrafiltration therapy in the outpatient setting MINNEAPOLIS, Nov. 04, 2024...

Nuwellis Announces Preliminary Results for Third Quarter of 2024

MINNEAPOLIS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company dedicated to transforming the lives of patients suffering from fluid overload, today...

Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer

MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to...

Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

MINNEAPOLIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that...

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.18-151.21.270.92376124471.03285749CS
4-0.23-18.41.251.450.92373980621.20038375CS
12-0.24-19.04761904761.264.190.923729935852.3238971CS
26-5.77-84.97790868926.798.2250.923717796562.64748322CS
52-17.88-94.603174603218.930.10.923726731877.5810518CS
156-4338.98-99.9764976959434064750.92371773472972.44891175CS
260-18499.28-99.994486575918500.3188650.923715087331317.24265946CS

NUWE - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Newellis?
El precio actual de las acciones de Newellis es US$ 1.02
¿Cuántas acciones de Newellis están en circulación?
Newellis tiene 4,373,968 acciones en circulación
¿Cuál es la capitalización de mercado de Newellis?
La capitalización de mercado de Newellis es USD 4.42M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Newellis?
Newellis ha negociado en un rango de US$ 0.9237 a US$ 30.10 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Newellis?
El ratio precio/beneficio de Newellis es -1.02
¿Cuál es el ratio de efectivo a ventas de Newellis?
El ratio de efectivo a ventas de Newellis es 2.61
¿Cuál es la moneda de reporte de Newellis?
Newellis presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Newellis?
El último ingresos anual de Newellis es USD 8.86M
¿Cuál es el último beneficio anual de Newellis?
El último beneficio anual de Newellis es USD -22.63M
¿Cuál es la dirección registrada de Newellis?
La dirección registrada de Newellis es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Newellis?
La dirección del sitio web de Newellis es www.nuwellis.com
¿En qué sector industrial opera Newellis?
Newellis opera en el sector ELECTROMEDICAL APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
120.01M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
76.64M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
33.95M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.61k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
120.4M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

NUWE Discussion

Ver más
glenn1919 glenn1919 4 semanas hace
NUWE.........................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783
👍️0
zendeli1 zendeli1 1 mes hace
restart soon
👍️ 1
tw0122 tw0122 1 mes hace
$2.25- + 23% ..2:40- 2.83 zone of interest breaks 2.83 gets interesting 
👍️0
glenn1919 glenn1919 1 mes hace
NUWE...................................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 1 mes hace
$2.30 + 24% NUWE 10k out reimbursement from Medicare/aid 400% increase 
👍 1 🔥 1
tw0122 tw0122 1 mes hace
$NUWE )2.18 + 20% Looks good a flip to $4 if gets going 
👍️0
Monksdream Monksdream 1 mes hace
NUWE, 10Q due 11/11
👍️0
tw0122 tw0122 1 mes hace
Will see $8s here in time .Nice dip $1.60s today added ..this one takes off again after Nov 4th news  Medicare Medicaid pay quadruples on Jan 1st.. 4x 
with the payment rate increasing to $1,639 a day from $413, Nuwellis said Monday in a statement.

The reassignment recognizes the effectiveness of the therapy for the treatment of fluid overload in heart
👍 1 🚀 1
tbonaces80 tbonaces80 2 meses hace
Have buys stops and short cover over $3.24. 
👍️0
tbonaces80 tbonaces80 2 meses hace
Close above $4
👍️0
tbonaces80 tbonaces80 2 meses hace
Thank you for 2.55. Loaded
👍️0
subslover subslover 2 meses hace
Circuit Breaker $3.29
👍️0
tbonaces80 tbonaces80 2 meses hace
1.9 float?  
👍️0
tw0122 tw0122 2 meses hace
Back to the $2s heck was a $20 stock not long ago
👍️0
GlitteringAstronaut77 GlitteringAstronaut77 2 meses hace
Is this a good long term buy?
👍️0
glenn1919 glenn1919 2 meses hace
nuwe.........................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 2 meses hace
$1.80 + 25% Time to pump this low floater again next up 1.85- 1.99
2.14- 2.27

2.40-2.84
👍️0
tw0122 tw0122 2 meses hace
Haven’t been able to absorb offering since August 23 ..what’s the next catalyst ?

sale of 496,901 shares of the Company’s common stock at a price of $1.8450 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 496,901 shares of common stock. The warrants have an exercise price of $1.72 per share, will be exercisable immediately following the date of issuance and will
👍️0
Awl416 Awl416 2 meses hace
Buy high sell low
👍️0
Muhbruh Muhbruh 3 meses hace
big catalyst coming up for this low floater
New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference taking place September 27-30, 2024
https://ir.nuwellis.com/news-releases/news-release-details/new-evidence-aquadex-ultrafiltration-therapy-be-presented-hfsa
👍️0
db101 db101 4 meses hace
NUWE 52w low… $1
👍️0
Monksdream Monksdream 4 meses hace
NUWE new 52 week low
👍️0
Monksdream Monksdream 4 meses hace
NUWE new 52=week low
👍️0
db101 db101 6 meses hace
New 52w low…
👍️0
dirtydozen911 dirtydozen911 6 meses hace
the R / S is in.
board decided to go easy on us,,,,only a 1:35 split
had this stock for a few years...was already at split adjusted $140 / share.
some of these bios ive kept in the barn for toooo long.
think i will relieve myself of this turd today ,and save the $38 re _org fee

dont have hardly any pennies left last 18 months or so. this otc crap and its mm`s all suck.

few years back u could make money in pinks......but its a rigged game now ......with runners shorted down to garbage by late afternoon

could hold these for 2 1/2 days and bail years ago......no longer interested in trading against algos, where a medium bid or offer causes all mm`s to shift instantly.

good luck alll....STAY WITH LISTED STOCKS!!

👍️0
dirtydozen911 dirtydozen911 6 meses hace
NO ONE WANTS THIS...?? ....hahahahahahahahahahahahah
defr14 on may 17....says R/S as HIGH AS 1 for 70 to be voted on in annual mtg
👍️0
The Night Stalker The Night Stalker 7 meses hace
nic3e
👍️0
The Night Stalker The Night Stalker 7 meses hace
starting
👍️0
db101 db101 7 meses hace
As the overall market starts to drop… NUWE will thrive
👍️0
Holtzi Holtzi 7 meses hace
I predict Im getting back in today :)
👍️0
db101 db101 7 meses hace
Any predictions?
👍️0
Holtzi Holtzi 7 meses hace
I guess Im not a fan of issuing shares and doing RS approx every 2 years to comply w/ NASDAQ
Thi s year is the RS Year. per May 1, 2024 Proxy Statement
👍️0
BurgerKing82 BurgerKing82 7 meses hace
Keep an eye on this one?
👍️0
SantaZar SantaZar 7 meses hace
$NUWE Chart from #DDAmanda - #1 Stock Screener :

Find Winners Early:



Z
👍️0
The Night Stalker The Night Stalker 7 meses hace
nice
👍️ 1
Holtzi Holtzi 8 meses hace
GOT OUT AT .3 TODAY BUT PLAN TO GET BACK IN AROUND .18??
👍️0
INV4 INV4 8 meses hace
Nuwellis, Inc. Announces First Quarter 2024 Financial ResultsNuwellis, Inc. Announces First Quarter 2024 Financial Results

Tue, May 7, 2024

https://finance.yahoo.com/news/nuwellis-inc-announces-first-quarter-120000903.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAABkXGl5nBDowplt7CUUbnRUbIEc9EdIJlYjwIvUTd0W2SVIKw0x9u__QaWxT8qI2-1mWxP8TPhc_mrpMBZoxJ0jklwvHpVt9C2gbJGOmKuaFtdP3Y7VwFSDB-lVwbcgF32mMwpFAAL-oukC9_f-Zolhy9jT5SPRD51AnFXe6vWxR

$NUWE
👍️0
Invest-in-America Invest-in-America 8 meses hace
NUWE: No "don't blink' today???
👍️0
Awl416 Awl416 8 meses hace
Hold on
👍️0
trendzone trendzone 8 meses hace
Once again the corrupt small hedge funds show up the next day on small stocks, that had run ups the past day, and turn on their grind down machines programs after they shorted the previous days highs, and profit off the scared little fliptards who sell out with their profits getting cut over night,if you want to beat the small wall street criminal hedge funds, you have to not be a wimp and sell out,and raise sell orders much higher,and let the scm bags get squeezed out of their corrupt short manipulation positions.
👍️0
Holtzi Holtzi 8 meses hace
Im in at .15 - think Im gonna hold until .50... Not sure yet
👍️0
GhosTraderX GhosTraderX 8 meses hace
Solid Day here, more to come...

Bought in at 0.18

Should test 0.30+

GhosT
👍️0
Holtzi Holtzi 8 meses hace
holding until Monday EOD I think
👍️0
INV4 INV4 8 meses hace
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

May 02, 2024

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian™. This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children.
The patented technology focuses on a design feature that allows healthcare providers to switch seamlessly between stationary operation and “transport” or “ambulation” mode, enabling unprecedented patient mobility. This innovative feature offers unmatched flexibility, allowing clinicians to tailor treatment plans to the specific needs of each young patient.

"We are thrilled to receive this patent allowance from the USPTO," said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “A core focus of our business strategy is developing novel technology and a strong IP portfolio. This innovative technology will empower healthcare providers with the ability to adapt treatment plans as needed, ultimately leading to improved patient care and outcomes for critically ill children and neonates.”

Nuwellis is currently developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. This development effort is funded in part by a $1.7 million grant from the National Institutes of Health (NIH). The company has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies Corporation (KBT), the grant recipient, in the design and development of a custom pediatric product that will enable clinicians to better care for babies with limited kidney function.

Nuwellis is committed to developing life-saving technologies specifically designed for the unique needs of pediatric patients. This patent allowance represents a significant advancement in the company's mission to revolutionize pediatric fluid management.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

https://ih.advfn.com/stock-market/NASDAQ/newellis-NUWE/stock-news/93767856/nuwellis-receives-uspto-notice-of-patent-allowance

$NUWE
👍️0
Jane1999 Jane1999 8 meses hace
I am holding for tomorrow
👍️0
Holtzi Holtzi 8 meses hace
Flippers and profit takers. Ill guess 3 of these as this stedy climbs untill financials, guessing other news will follow the report
👍️0
Holtzi Holtzi 8 meses hace
Guessing a better report than was anticipated??
👍️0
Holtzi Holtzi 8 meses hace
Anyone have an exit price in mind??
👍️0
Holtzi Holtzi 8 meses hace
hoping for a good report EOW
👍️0
Holtzi Holtzi 8 meses hace
NICE PRE MARKET TRADING AND GOOD NEWS
👍️0

Su Consulta Reciente

Delayed Upgrade Clock